RECIPHARM
Recipharm was established in Sweden in 1995 and has since grown to become a leading Contract Development and Manufacturing Organisation (CDMO). Headquartered in Jordbro, Recipharm employs around 3,500 people and the Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For over 20 years Recipharm has focussed on supporting pharmaceutical companies in taking their products from early development through to commercial manufacturing. Throughout the entire product lifecycle, Recipharm is there... for its clients. Time and time again, Recipharm has delivered innovative solutions. Recipharm has been around for a while and they are proud of the company they have built which is why they want people to know they are here for them today and they will be here for them tomorrow too. That’s the Recipharm way. There are lots of CDMOs in the world. But none quite like Recipharm. Despite the scale and size of their company, they conduct their business in the right way, by respecting all stakeholders at all times and delivering value for money to their clients.
RECIPHARM
Industry:
Biotechnology Manufacturing Medical Pharmaceutical
Founded:
1995-01-01
Address:
Jordbro, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.recipharm.com
Total Employee:
1001+
Status:
Active
Contact:
+ 46 8 602 52 00
Email Addresses:
[email protected]
Total Funding:
241.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager Content Delivery Network Domain Not Resolving Mobile Non Scaleable Content Euro Organization Schema IPv6
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-02-01 | GenIbet | GenIbet acquired by Recipharm | N/A |
| 2019-11-18 | Consort Medical | Consort Medical acquired by Recipharm | N/A |
| 2018-10-01 | Sanofi - business | Sanofi - business acquired by Recipharm | N/A |
| 2017-02-20 | Kemwell’s pharmaceutical businesses | Kemwell’s pharmaceutical businesses acquired by Recipharm | N/A |
| 2016-04-19 | Cirrus Pharmaceuticals | Cirrus Pharmaceuticals acquired by Recipharm | 13.6 B INR |
| 2016-04-18 | Kemwell Biopharma | Kemwell Biopharma acquired by Recipharm | N/A |
| 2016-02-23 | MITIM S.r.l | MITIM S.r.l acquired by Recipharm | 75.5 M USD |
| 2015-10-21 | Nitin Lifesciences Ltd | Nitin Lifesciences Ltd acquired by Recipharm | 824 M SEK |
| 2015-06-06 | OnTarget Chemistry | OnTarget Chemistry acquired by Recipharm | N/A |
| 2014-12-01 | Flamel Technologies | Flamel Technologies acquired by Recipharm | N/A |
Investors List
Swedbank
Swedbank investment in Post-IPO Debt - Recipharm
DNB
DNB investment in Post-IPO Debt - Recipharm
Svenska Handelsbanken
Svenska Handelsbanken investment in Post-IPO Debt - Recipharm
Newest Events participated
Participated in The Future of Swedish & Danish Life Science 2017
on 2017-03-30 as exhibitor
Participated in The Future of Swedish & Danish Life Science 2017
on 2017-03-30 as sponsor
Official Site Inspections
http://www.recipharm.com Semrush global rank: 2.21 M Semrush visits lastest month: 8.78 K
- Host name: ec2-52-17-142-199.eu-west-1.compute.amazonaws.com
- IP address: 52.17.142.199
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Recipharm"
Recipharm
Recipharm is a world leading CDMO. Supporting customers in bringing innovations to market, from early stage development to commercial manufacturing.See details»
About Us | Pharmaceutical CDMO - Recipharm
Recipharm is an experienced, global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how and customer connectivity.See details»
Recipharm - Wikipedia
Recipharm AB is one of the five largest pharmaceutical contract development and manufacturing organizations in the world, with production facilities in Sweden, France, Germany, Italy, Spain, Portugal, India and the UK as well as development sites in Sweden, Israel and the United States. The Swedish-based company employs around 5,200 people and operates over 18 facilities. The c…See details»
Bespak completes separation from Recipharm
Apr 2, 2024 · Both Bespak and Recipharm are backed by EQT Private Equity. The spin-out has created a leading global contract development and manufacturing organisation (CDMO) focused on drug-device combination …See details»
Meet our people - Recipharm
Working with Recipharm means having the freedom, support, and possibilities to build your career while enjoying work-life balance. Your time with us can take you wherever you want to go: from internships and junior positions up to more …See details»
Recipharm - The Org
Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 20 years’ experience.See details»
Recipharm - LinkedIn
Recipharm is an experienced, global CDMO dedicated to meeting pharmaceutical companies’ evolving needs through operational excellence, scientific know-how and customer connectivity.See details»
Recipharm - EQT Group
Recipharm is a global Specialty CDMO focused on attractive growth niches including high-potency small molecules, lyophilization, pre-filled syringe technologies and mRNA, leveraging its leading positions in oral solid dosage, …See details»
Recipharm Harmonizes its Global Quality Operations …
PLEASANTON, CA — Dec. 19, 2023 — Veeva Systems (NYSE: VEEV) today announced that Recipharm, a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS, Veeva Vault QualityDocs, …See details»
Private equity firm EQT to acquire Sweden's Recipharm for $2.1B
Dec 14, 2020 · The private equity firm launched an offer to Recipharm's shareholders and bondholders to tender all their class B shares and convertible bonds to Roar BidCo, a unit of …See details»
Recipharm | World Pharma Today
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees.See details»
Recipharm - NCBioNetwork.org
Recipharm is a leading global pharmaceutical Contract Development and Manufacturing Organisation (CDMO). We provide pharmaceutical companies around the world with tailor …See details»
Recipharm - PharmaSource
Aug 1, 2024 · Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, development and technology services.See details»
Recibiopharm | Biologics CDMO | Vibalogics, Arranta Bio
Recipharm acquired Arranta Bio, GenIbet and Vibalogics to bolster its biologics offering. Discover more about the newly formed advanced therapies CDMO.See details»
Recipharm Company Profile 2024: Valuation, Funding & Investors
Operator of pharmaceutical contract development and manufacturing organization (CDMO) intended for pharmaceutical and biotech companies. The company's services cover the entire …See details»
Recipharm bolsters global production facilities
Oct 8, 2024 · Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm is expanding its manufacturing capacity …See details»
Pharmaceutical Commercial Manufacturing & Supply | Recipharm
From procurement to full-scale manufacturing, distribution, tech-transfer, stability studies, and life cycle management, we have the capabilities to support you in delivering your product to …See details»
Recipharm AB sells majority stake in Nitin Lifesciences Limited to
Oct 3, 2023 · EY provided financial advisory services to Recipharm AB on the divestment of majority stake in Nitin Lifesciences Limited to TA Associates-owned Synokem …See details»
Leadership Lessons from Luc Burgard, COO of Recipharm
2 days ago · Leadership Lessons from the Chief Operations Officer. We had the opportunity to engage in conversation with Luc Burgard, the distinguished Chief Operating Officer of …See details»
Navigating Complex Pharmaceutical Needs | Recipharm
The global Contract Development and Manufacturing Organization (CDMO) industry, valued at $94.17 billion in 2022, is anticipated to reach $172.02 billion by 2032. This sector is …See details»